Pharmafile Logo

UK Vaccine Taskforce

- PMLiVE

NeuroRx, Relief Therapeutics’ COVID-19 drug demonstrates early potential

Drug produced rapid recovery in critically-ill patients

- PMLiVE

UK will provide millions of 90-minute COVID-19 tests over the coming months

Tests will be rolled out ahead of the winter months

- PMLiVE

US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine

Both companies are also in talks with EU for access to candidate

- PMLiVE

J&J’s COVID-19 vaccine generates positive pre-clinical results

Experimental vaccine begins first-in-human trial this month

Covid-19 drives change in long-term conditions management

Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore how patients are being empowered to manage their conditions at home

Wilmington Healthcare

- PMLiVE

Gilead’s top-line slips 10% as demand for HIV/hepatitis C drugs drops

Disruption to uptake of HIV and hepatitis C drugs caused by pandemic

VR/AR Applications for Training and Healthcare

In the latest episode of Impetus Digital's Fireside Chat, I sit down with Mike Waldron, who is the CEO and Co-Founder of Propel VR. We discuss how virtual reality (VR)...

Impetus Digital

Secondary effects of COVID-19 on the healthcare system and patients

We are getting to the point where we need to start considering the long-term effects on the healthcare system when making decisions.

Impetus Digital

AstraZeneca AZ

AstraZeneca escapes pandemic impact as new drugs bolster revenues

Earnings climbed above expectations in the second quarter

- PMLiVE

Moderna looks to price COVID-19 vaccine at $50-$60 per course

Shines spotlight on pricing strategies for potential vaccines

- PMLiVE

UK government and GSK/Sanofi sign COVID-19 vaccine supply deal

UK adds to its arsenal of potential vaccine candidates

- PMLiVE

Roche’s Actemra fails in late-stage severe COVID-19 study

Anti-inflammatory drug unable to improve clinical status of hospitalised patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links